Clinical trial
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With…
NCT00313976 · Bayer, Industry · Withdrawn
Key facts
| NCT number | NCT00313976 |
|---|---|
| Title | Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) |
| Official title | A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis |
| Lead sponsor | Bayer, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) |
| Enrollment | 0 |
| First posted | Apr 12, 2006 |
| Last update posted | Mar 10, 2015 |
| Countries | Denmark, Sweden |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: